Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 04.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 16.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 26.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 26.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 28.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | , or otherwise, except as required by law. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
Stammdaten
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Unternehmen & Branche
| Name | OMNICELL, INC. |
|---|---|
| Ticker | OMCL |
| CIK | 0000926326 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Healthcare Information Services |
| SIC | 3571 · Electronic Computers |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,95 Mrd. USD |
| Beta | 0,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,184,845,000 | 2,052,000 | 0.04 | 1,974,720,000 | 1,231,814,000 |
| 2025-09-30 | 10-Q | 310,631,000 | 5,462,000 | 0.12 | 1,948,597,000 | 1,220,902,000 |
| 2025-06-30 | 10-Q | 290,562,000 | 5,639,000 | 0.12 | 2,145,496,000 | 1,263,619,000 |
| 2025-03-31 | 10-Q | 269,668,000 | -7,023,000 | -0.15 | 2,151,470,000 | 1,257,100,000 |
| 2024-12-31 | 10-K | 1,112,238,000 | 12,531,000 | 0.27 | 2,120,960,000 | 1,243,313,000 |
| 2024-09-30 | 10-Q | 282,420,000 | 8,630,000 | 0.19 | 2,303,588,000 | 1,231,328,000 |
| 2024-06-30 | 10-Q | 276,788,000 | 3,735,000 | 0.08 | 2,291,657,000 | 1,202,808,000 |
| 2024-03-31 | 10-Q | 246,151,000 | -15,676,000 | -0.34 | 2,283,755,000 | 1,188,597,000 |
| 2023-12-31 | 10-K | 1,147,112,000 | -20,371,000 | -0.45 | 2,226,878,000 | 1,188,954,000 |
| 2023-09-30 | 10-Q | 298,663,000 | 5,553,000 | 0.12 | 2,221,575,000 | 1,187,436,000 |
| 2023-06-30 | 10-Q | 298,973,000 | 3,451,000 | 0.08 | 2,193,872,000 | 1,163,565,000 |
| 2023-03-31 | 10-Q | 290,629,000 | -15,000,000 | -0.33 | 2,250,838,000 | 1,142,541,000 |
| 2022-12-31 | 10-K | 1,295,947,000 | 5,648,000 | 0.12 | 2,210,758,000 | 1,130,137,000 |
| 2022-09-30 | 10-Q | 348,059,000 | 16,774,000 | 0.37 | 2,179,685,000 | 1,135,395,000 |
| 2022-06-30 | 10-Q | 331,386,000 | 9,069,000 | 0.20 | 2,131,458,000 | 1,092,637,000 |
| 2022-03-31 | 10-Q | 318,828,000 | 8,213,000 | 0.17 | 2,122,588,000 | 1,074,741,000 |
| 2021-12-31 | 10-K | 1,132,018,000 | 77,849,000 | 1.62 | 2,142,496,000 | 1,146,689,000 |
| 2021-09-30 | 10-Q | 296,402,000 | 29,317,000 | 0.61 | 2,051,471,000 | 1,111,336,000 |
| 2021-06-30 | 10-Q | 272,739,000 | 20,424,000 | 0.43 | 1,960,994,000 | 1,052,572,000 |
| 2021-03-31 | 10-Q | 251,843,000 | 14,127,000 | 0.30 | 1,886,623,000 | 1,011,011,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -7,405 | 34.69 | -256,879.45 | -91,8% | |
| 2026-02-17 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -4,243 | 36.59 | -155,251.37 | -55,5% | |
| 2026-01-08 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -6,106 | 49.90 | -304,689.40 | -108,9% | |
| 2025-12-16 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -278 | 43.30 | -12,037.40 | -4,3% | |
| 2025-12-03 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -6,106 | 39.90 | -243,629.40 | -87,1% | |
| 2025-12-01 | LIPPS RANDALL A | Director, Officer, CHAIRMAN, PRESIDENT AND CEO | Open Market Sale | -28,250 | 35.97 | -1,016,093.18 | -363,1% | |
| 2025-11-17 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -3,473 | 34.90 | -121,207.70 | -43,3% | |
| 2025-09-12 | Manley Corey J | Officer, EVP&CHIEF LEGAL/ADMIN OFFICER | Open Market Sale | -3,880 | 33.25 | -129,010.00 | -46,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.